Literature DB >> 29080397

Astatine.

Geerd-J Meyer1.   

Abstract

This educational review describes and summarizes the historic discovery of element 85, the experiments leading to its physical and chemical characterization and comparison with its lighter homologue iodine. The half-lives of its longest living isotopes 210 At and 211 At with 8.3 and 7.22 hours respectively together with their alpha decay characteristics made these isotopes interesting for radiation biological research. However, the lack of stable isotopes of astatine presents a strong challenge for all characterizations. Nevertheless, the decay characteristics especially of 211 At stimulated several research groups to develop labelling strategies for the preparation of astatinated radiopharmaceuticals for targeted alpha radiation therapy. Because of the distinct differences in the chemical behaviour of astatine, when compared with iodine, these approaches are quite challenging. Accordingly, quite different labelling strategies have been tested, namely nucleophilic and electrophilic substitution reactions as well as complex forming strategies. Classic and new developments for the preparation of these compounds are reviewed.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29080397     DOI: 10.1002/jlcr.3573

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  6 in total

Review 1.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

2.  An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy.

Authors:  Ronnie C Mease; Choong Mo Kang; Vivek Kumar; Sangeeta Ray Banerjee; Il Minn; Mary Brummet; Kathleen L Gabrielson; Yutian Feng; Andrew Park; Ana P Kiess; George Sgouros; Ganesan Vaidyanathan; Michael R Zalutsky; Martin G Pomper
Journal:  J Nucl Med       Date:  2021-06-04       Impact factor: 10.057

3.  Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy.

Authors:  Yang Liu; Zhengyuan Zhou; Yutian Feng; Xiao-Guang Zhao; Ganesan Vaidyanathan; Michael R Zalutsky; Tuan Vo-Dinh
Journal:  Int J Nanomedicine       Date:  2021-10-28

4.  Covalent core-radiolabeling of polymeric micelles with 125I/211At for theranostic radiotherapy.

Authors:  Emanuel Sporer; Christian B M Poulie; Tom Bäck; Sture Lindegren; Holger Jensen; Paul J Kempen; Andreas Kjaer; Matthias M Herth; Andreas I Jensen
Journal:  Nanotheranostics       Date:  2022-07-18

Review 5.  Production, purification and availability of 211At: Near term steps towards global access.

Authors:  Yutian Feng; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2021-06-10       Impact factor: 2.947

6.  Development of an autonomous solvent extraction system to isolate astatine-211 from dissolved cyclotron bombarded bismuth targets.

Authors:  Matthew J O'Hara; Anthony J Krzysko; Donald K Hamlin; Yawen Li; Eric F Dorman; D Scott Wilbur
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.